Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05296382 · ClinicalTrials.gov registry record · Phase 1
Bioavailability of Tebipenem (SPR994) Crushed Tablet
A Phase 1 study of Relative Bioavailability, sponsored by Hartford Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05296382 is a Phase 1 study of Relative Bioavailability that has completed, run by Hartford Hospital. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05296382, a Phase 1 study of Relative Bioavailability, has completed, sponsored by Hartford Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to measure the amount of the antibiotic, tebipenem (SPR994) that is bioavailable after crushing the tablet and administering through a feeding tube with and without tube feeds.
Conditions Studied
Interventions
- DRUG Tebipenem tablet form
- OTHER Tube feeds
Study Locations (1)
Connecticut
- Hartford Hospital - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-04-01 |
| Est. Completion | 2022-12-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05296382
The ClinicalTrials.gov registry entry for NCT05296382 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hartford Hospital, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relative Bioavailability appearing as the primary indexed condition, and to 2 interventions - of which Tebipenem tablet form is the first listed.
NCT05296382 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT05296382 about?
NCT05296382 is a clinical study titled "Bioavailability of Tebipenem (SPR994) Crushed Tablet". The purpose of this study is to measure the amount of the antibiotic, tebipenem (SPR994) that is bioavailable after crushing the tablet and administering through a feeding tube with and without tube feeds.
What is the current status of trial NCT05296382?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2022-04-01. Estimated completion is 2022-12-23.
What conditions does trial NCT05296382 study?
This clinical trial studies the following conditions: Relative Bioavailability.
What interventions are being tested in trial NCT05296382?
The interventions under investigation include: Tebipenem tablet form (DRUG), Tube feeds (OTHER).
Who is sponsoring clinical trial NCT05296382?
This trial is sponsored by Hartford Hospital, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05296382 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.